CT Biotech Firm Working Drug to Treat Stroke, Brain Injuries

Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Last week, Astrocyte put out word that Stroke, a peer-reviewed journal, had published the results of preclinical studies of the drug, known for now as AST-004. The lack of available treatments for stroke is a major unmet medical need, one that could qualify Astrocyte’s drug development for fast-tracking if the results of upcoming human trials are sufficiently promising, according to Ted Liston, Astrocyte’s vice president of research. Read more >>